 | • レポートコード：MRC2-11QY04606 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は鎌状赤血球貧血治療薬のグローバル市場について調査・分析したレポートです。種類別（輸血、薬物療法、骨髄移植）市場規模、用途別（子供、大人）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別鎌状赤血球貧血治療薬の競争状況、市場シェア ・世界の鎌状赤血球貧血治療薬市場：種類別市場規模 2015年-2020年（輸血、薬物療法、骨髄移植） ・世界の鎌状赤血球貧血治療薬市場：種類別市場規模予測 2021年-2026年（輸血、薬物療法、骨髄移植） ・世界の鎌状赤血球貧血治療薬市場：用途別市場規模 2015年-2020年（子供、大人） ・世界の鎌状赤血球貧血治療薬市場：用途別市場規模予測 2021年-2026年（子供、大人） ・北米の鎌状赤血球貧血治療薬市場分析：米国、カナダ ・ヨーロッパの鎌状赤血球貧血治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの鎌状赤血球貧血治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の鎌状赤血球貧血治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの鎌状赤血球貧血治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Addmedica、Gamida Cell、GlycoMimetics、Pfizer、Novartis、Global Blood Therapeutics、Micelle BioPharma、Bluebird Bio、Prolong Pharmaceuticals、Modus Therapeutics、Sangamo Biosciences、Bioverativ、Imara、Ironwood Pharmaceuticals ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
In the last several years, global market of Sickle Cell Anemia Therapeutics developed rapidly, with an average growth rate of 13.32% during 2013 to 2017. In 2017, global revenue of Sickle Cell Anemia Therapeutics is nearly 1900 M USD.
Market Analysis and Insights: Global Sickle-cell Anemia Therapeutics Market
The global Sickle-cell Anemia Therapeutics market size is projected to reach US$ 1903 million by 2026, from US$ 1633.2 million in 2020, at a CAGR of 15.0%% during 2021-2026.
Global Sickle-cell Anemia Therapeutics Scope and Market Size
Sickle-cell Anemia Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Sickle-cell Anemia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Market segment by Type, the product can be split into
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Market segment by Application, split into
Child
Adult
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Sickle-cell Anemia Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Sickle-cell Anemia Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Blood Transfusion
1.4.3 Pharmacotherapy
1.4.4 Bone Marrow Transplant
1.5 Market by Application
1.5.1 Global Sickle-cell Anemia Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Child
1.5.3 Adult
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Sickle-cell Anemia Therapeutics Market Perspective (2015-2026)
2.2 Global Sickle-cell Anemia Therapeutics Growth Trends by Regions
2.2.1 Sickle-cell Anemia Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Sickle-cell Anemia Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Sickle-cell Anemia Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Sickle-cell Anemia Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Sickle-cell Anemia Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Sickle-cell Anemia Therapeutics Players by Market Size
3.1.1 Global Top Sickle-cell Anemia Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Sickle-cell Anemia Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Sickle-cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Sickle-cell Anemia Therapeutics Market Concentration Ratio
3.2.1 Global Sickle-cell Anemia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Sickle-cell Anemia Therapeutics Revenue in 2019
3.3 Sickle-cell Anemia Therapeutics Key Players Head office and Area Served
3.4 Key Players Sickle-cell Anemia Therapeutics Product Solution and Service
3.5 Date of Enter into Sickle-cell Anemia Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Sickle-cell Anemia Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Sickle-cell Anemia Therapeutics Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
5.2 Global Sickle-cell Anemia Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Sickle-cell Anemia Therapeutics Market Size (2015-2020)
6.2 Sickle-cell Anemia Therapeutics Key Players in North America (2019-2020)
6.3 North America Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
6.4 North America Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Sickle-cell Anemia Therapeutics Market Size (2015-2020)
7.2 Sickle-cell Anemia Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
7.4 Europe Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Sickle-cell Anemia Therapeutics Market Size (2015-2020)
8.2 Sickle-cell Anemia Therapeutics Key Players in China (2019-2020)
8.3 China Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
8.4 China Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Sickle-cell Anemia Therapeutics Market Size (2015-2020)
9.2 Sickle-cell Anemia Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
9.4 Japan Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Sickle-cell Anemia Therapeutics Market Size (2015-2020)
10.2 Sickle-cell Anemia Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Sickle-cell Anemia Therapeutics Market Size (2015-2020)
11.2 Sickle-cell Anemia Therapeutics Key Players in India (2019-2020)
11.3 India Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
11.4 India Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Sickle-cell Anemia Therapeutics Market Size (2015-2020)
12.2 Sickle-cell Anemia Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Addmedica
13.1.1 Addmedica Company Details
13.1.2 Addmedica Business Overview
13.1.3 Addmedica Sickle-cell Anemia Therapeutics Introduction
13.1.4 Addmedica Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020))
13.1.5 Addmedica Recent Development
13.2 Gamida Cell
13.2.1 Gamida Cell Company Details
13.2.2 Gamida Cell Business Overview
13.2.3 Gamida Cell Sickle-cell Anemia Therapeutics Introduction
13.2.4 Gamida Cell Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.2.5 Gamida Cell Recent Development
13.3 GlycoMimetics
13.3.1 GlycoMimetics Company Details
13.3.2 GlycoMimetics Business Overview
13.3.3 GlycoMimetics Sickle-cell Anemia Therapeutics Introduction
13.3.4 GlycoMimetics Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.3.5 GlycoMimetics Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Sickle-cell Anemia Therapeutics Introduction
13.4.4 Pfizer Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Sickle-cell Anemia Therapeutics Introduction
13.5.4 Novartis Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Global Blood Therapeutics
13.6.1 Global Blood Therapeutics Company Details
13.6.2 Global Blood Therapeutics Business Overview
13.6.3 Global Blood Therapeutics Sickle-cell Anemia Therapeutics Introduction
13.6.4 Global Blood Therapeutics Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.6.5 Global Blood Therapeutics Recent Development
13.7 Micelle BioPharma
13.7.1 Micelle BioPharma Company Details
13.7.2 Micelle BioPharma Business Overview
13.7.3 Micelle BioPharma Sickle-cell Anemia Therapeutics Introduction
13.7.4 Micelle BioPharma Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.7.5 Micelle BioPharma Recent Development
13.8 Bluebird Bio
13.8.1 Bluebird Bio Company Details
13.8.2 Bluebird Bio Business Overview
13.8.3 Bluebird Bio Sickle-cell Anemia Therapeutics Introduction
13.8.4 Bluebird Bio Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.8.5 Bluebird Bio Recent Development
13.9 Prolong Pharmaceuticals
13.9.1 Prolong Pharmaceuticals Company Details
13.9.2 Prolong Pharmaceuticals Business Overview
13.9.3 Prolong Pharmaceuticals Sickle-cell Anemia Therapeutics Introduction
13.9.4 Prolong Pharmaceuticals Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.9.5 Prolong Pharmaceuticals Recent Development
13.10 Modus Therapeutics
13.10.1 Modus Therapeutics Company Details
13.10.2 Modus Therapeutics Business Overview
13.10.3 Modus Therapeutics Sickle-cell Anemia Therapeutics Introduction
13.10.4 Modus Therapeutics Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
13.10.5 Modus Therapeutics Recent Development
13.11 Sangamo Biosciences
10.11.1 Sangamo Biosciences Company Details
10.11.2 Sangamo Biosciences Business Overview
10.11.3 Sangamo Biosciences Sickle-cell Anemia Therapeutics Introduction
10.11.4 Sangamo Biosciences Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
10.11.5 Sangamo Biosciences Recent Development
13.12 Bioverativ
10.12.1 Bioverativ Company Details
10.12.2 Bioverativ Business Overview
10.12.3 Bioverativ Sickle-cell Anemia Therapeutics Introduction
10.12.4 Bioverativ Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
10.12.5 Bioverativ Recent Development
13.13 Imara
10.13.1 Imara Company Details
10.13.2 Imara Business Overview
10.13.3 Imara Sickle-cell Anemia Therapeutics Introduction
10.13.4 Imara Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
10.13.5 Imara Recent Development
13.14 Ironwood Pharmaceuticals
10.14.1 Ironwood Pharmaceuticals Company Details
10.14.2 Ironwood Pharmaceuticals Business Overview
10.14.3 Ironwood Pharmaceuticals Sickle-cell Anemia Therapeutics Introduction
10.14.4 Ironwood Pharmaceuticals Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020)
10.14.5 Ironwood Pharmaceuticals Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Sickle-cell Anemia Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Sickle-cell Anemia Therapeutics Revenue
Table 3. Ranking of Global Top Sickle-cell Anemia Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Sickle-cell Anemia Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Blood Transfusion
Table 6. Key Players of Pharmacotherapy
Table 7. Key Players of Bone Marrow Transplant
Table 8. Global Sickle-cell Anemia Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Sickle-cell Anemia Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Sickle-cell Anemia Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Sickle-cell Anemia Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Sickle-cell Anemia Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Sickle-cell Anemia Therapeutics Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Sickle-cell Anemia Therapeutics Market Growth Strategy
Table 18. Main Points Interviewed from Key Sickle-cell Anemia Therapeutics Players
Table 19. Global Sickle-cell Anemia Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 20. Global Sickle-cell Anemia Therapeutics Market Share by Players (2015-2020)
Table 21. Global Top Sickle-cell Anemia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Sickle-cell Anemia Therapeutics as of 2019)
Table 22. Global Sickle-cell Anemia Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Sickle-cell Anemia Therapeutics Product Solution and Service
Table 25. Date of Enter into Sickle-cell Anemia Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 28. Global Sickle-cell Anemia Therapeutics Market Size Share by Type (2015-2020)
Table 29. Global Sickle-cell Anemia Therapeutics Revenue Market Share by Type (2021-2026)
Table 30. Global Sickle-cell Anemia Therapeutics Market Size Share by Application (2015-2020)
Table 31. Global Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 32. Global Sickle-cell Anemia Therapeutics Market Size Share by Application (2021-2026)
Table 33. North America Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 35. North America Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 36. North America Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 37. North America Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 38. North America Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 39. Europe Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 41. Europe Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 43. Europe Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 45. China Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 46. China Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 47. China Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 48. China Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 49. China Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 50. China Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 51. Japan Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 53. Japan Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 55. Japan Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 59. Southeast Asia Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 61. Southeast Asia Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 63. India Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 64. India Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 65. India Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 66. India Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 67. India Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 68. India Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Sickle-cell Anemia Therapeutics Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Sickle-cell Anemia Therapeutics Market Share (2019-2020)
Table 71. Central & South America Sickle-cell Anemia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Sickle-cell Anemia Therapeutics Market Share by Type (2015-2020)
Table 73. Central & South America Sickle-cell Anemia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Sickle-cell Anemia Therapeutics Market Share by Application (2015-2020)
Table 75. Addmedica Company Details
Table 76. Addmedica Business Overview
Table 77. Addmedica Product
Table 78. Addmedica Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 79. Addmedica Recent Development
Table 80. Gamida Cell Company Details
Table 81. Gamida Cell Business Overview
Table 82. Gamida Cell Product
Table 83. Gamida Cell Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 84. Gamida Cell Recent Development
Table 85. GlycoMimetics Company Details
Table 86. GlycoMimetics Business Overview
Table 87. GlycoMimetics Product
Table 88. GlycoMimetics Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 89. GlycoMimetics Recent Development
Table 90. Pfizer Company Details
Table 91. Pfizer Business Overview
Table 92. Pfizer Product
Table 93. Pfizer Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 94. Pfizer Recent Development
Table 95. Novartis Company Details
Table 96. Novartis Business Overview
Table 97. Novartis Product
Table 98. Novartis Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 99. Novartis Recent Development
Table 100. Global Blood Therapeutics Company Details
Table 101. Global Blood Therapeutics Business Overview
Table 102. Global Blood Therapeutics Product
Table 103. Global Blood Therapeutics Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 104. Global Blood Therapeutics Recent Development
Table 105. Micelle BioPharma Company Details
Table 106. Micelle BioPharma Business Overview
Table 107. Micelle BioPharma Product
Table 108. Micelle BioPharma Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 109. Micelle BioPharma Recent Development
Table 110. Bluebird Bio Business Overview
Table 111. Bluebird Bio Product
Table 112. Bluebird Bio Company Details
Table 113. Bluebird Bio Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 114. Bluebird Bio Recent Development
Table 115. Prolong Pharmaceuticals Company Details
Table 116. Prolong Pharmaceuticals Business Overview
Table 117. Prolong Pharmaceuticals Product
Table 118. Prolong Pharmaceuticals Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 119. Prolong Pharmaceuticals Recent Development
Table 120. Modus Therapeutics Company Details
Table 121. Modus Therapeutics Business Overview
Table 122. Modus Therapeutics Product
Table 123. Modus Therapeutics Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 124. Modus Therapeutics Recent Development
Table 125. Sangamo Biosciences Company Details
Table 126. Sangamo Biosciences Business Overview
Table 127. Sangamo Biosciences Product
Table 128. Sangamo Biosciences Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 129. Sangamo Biosciences Recent Development
Table 130. Bioverativ Company Details
Table 131. Bioverativ Business Overview
Table 132. Bioverativ Product
Table 133. Bioverativ Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 134. Bioverativ Recent Development
Table 135. Imara Company Details
Table 136. Imara Business Overview
Table 137. Imara Product
Table 138. Imara Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 139. Imara Recent Development
Table 140. Ironwood Pharmaceuticals Company Details
Table 141. Ironwood Pharmaceuticals Business Overview
Table 142. Ironwood Pharmaceuticals Product
Table 143. Ironwood Pharmaceuticals Revenue in Sickle-cell Anemia Therapeutics Business (2015-2020) (Million US$)
Table 144. Ironwood Pharmaceuticals Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Sickle-cell Anemia Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Blood Transfusion Features
Figure 3. Pharmacotherapy Features
Figure 4. Bone Marrow Transplant Features
Figure 5. Global Sickle-cell Anemia Therapeutics Market Share by Application: 2020 VS 2026
Figure 6. Child Case Studies
Figure 7. Adult Case Studies
Figure 8. Sickle-cell Anemia Therapeutics Report Years Considered
Figure 9. Global Sickle-cell Anemia Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Sickle-cell Anemia Therapeutics Market Share by Regions: 2020 VS 2026
Figure 11. Global Sickle-cell Anemia Therapeutics Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Sickle-cell Anemia Therapeutics Market Share by Players in 2019
Figure 14. Global Top Sickle-cell Anemia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Sickle-cell Anemia Therapeutics as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Sickle-cell Anemia Therapeutics Revenue in 2019
Figure 16. North America Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Sickle-cell Anemia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
鎌状赤血球の世界市場（～2026年） The global sickle cell market is expected to grow in future due to rising African-American population, economic growth, increasing healthcare expenditure and prevalence of sickle cell. Key trends of this market include progressing drug pipeline and rising research grants. However, there are some fac…- 貧血治療薬の世界市場（～2026年） Anemia is a disease in which the blood does not carry the optimal amount of oxygen due to red blood cell count or a severe reduction, in our report, it studies iron deficiency anemia, sickle cell anemia, pernicious anemia, hemolytic anemia. The iron deficiency anemia market segment accounted for the…
- 鎌状赤血球症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Sickle Cell Disease Drug Market The global Sickle Cell Disease Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Sickle Cell Disease Drug Scope and Market Size Sickle Cell Diseas…
- 血管閉塞症・鎌状赤血球症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-20…
- 幹細胞臍帯血の世界市場（～2026年） Umbilical cord blood (UCB) stem cells have gained much significance in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood that remains in the attached umbilical cord and placenta after childbirth. Stem cells that UCB contains are considered uniq…